Recombinant Human Follitropin(Livzon MABPharm)

Main purpose: To evaluate the similarity of the efficacy of recombinant human follicle-stimulating hormone injection (LZ-B-01) and GONAL-F® in obtaining oocytes in controlled superovulation therapy for assisted reproductive technology (ART), and to compare their equivalence. Secondary objectives: 1) To evaluate the differences in follicular development and endocrine characteristics between LZ-B-01 and GONAL-F® for ART controlled ovarian hyperstimulation therapy; 2) To evaluate the differences in efficacy indicators such as serum human chorionic gonadotropin/β-human chorionic gonadotropin (hCG/β-hCG) positive rate, clinical pregnancy rate, and ongoing pregnancy rate between LZ-B-01 and GONAL-F® for ART controlled ovarian hyperstimulation therapy; 3) To evaluate the safety differences between LZ-B-01 and GONAL-F® for ART controlled ovarian hyperstimulation therapy; 4) To evaluate the differences in immunogenicity between LZ-B-01 and GONAL-F® for ART controlled ovarian hyperstimulation therapy; 5) To evaluate the pharmacokinetic (PK) characteristics of LZ-B-01 for ART controlled ovarian hyperstimulation therapy.